deoxypyridinoline

Subscribe to Selected New Research on deoxypyridinoline

694 relevant articles (19 outcomes, 71 trials/studies) found for this Bio-Agent

Description: structure given in first source

Also Known As:

N-(5-amino-5-carboxypentyl)-3-hydroxy-4-(2-amino-2-carboxyethyl)-5-(3-amino-3-carboxypropyl)pyridine; deoxypyridinoline, stereoisomer; lysylpyridinoline; Pyridinium, 4-(2-amino-2-carboxyethyl)-1-(5-amino-5-carboxypentyl)-3-(3-amino-3-carboxypropyl)-5-hydroxy-, hydroxide, inner salt, stereoisomer

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Amino Acids: 8786

deoxypyridinoline: 694

Experts

1.	Yasunori, Kageyama: 1 article (09/2008)
2.	Akira, Nagano: 1 article (09/2008)
3.	Hayato, Kobayashi: 1 article (09/2008)
4.	Masaaki, Takahashi: 1 article (09/2008)
5.	Tetsuyuki, Nagafusa: 1 article (09/2008)
6.	Karaoglu, A: 1 article (12/2007)
7.	Topkan, E: 1 article (12/2007)
8.	Schneider, U: 1 article (07/2006)
9.	Kalke, A E: 1 article (07/2006)
10.	Hermsen, D: 1 article (07/2006)

Related Diseases

1.	Bone Resorption 05/01/2008 - "Furthermore, markers of osteoclastic bone resorption, including osteoclast number, osteoclast surface, and urinary deoxypyridinoline excretion, were again significantly greater only in the triply NOS(-/-) mice. " 02/01/2002 - "Urinary deoxypyridinoline, an index of bone resorption, was significantly greater in TS rats, but unaltered by (-)Cu. " 01/01/2009 - "PURPOSE: Deoxypyridinoline (DPD) is a derivative of hydroxypyridinium, which is released during bone resorption into the blood stream and is eliminated unmodified with urine. " 10/01/1994 - "We now describe the development of an immunoassay (ELISA) based on a monoclonal antibody for free deoxypyridinoline (Dpd) and its use in healthy individuals and patients with bone-related disorders to measure the urinary excretion of Dpd as an improved assessment of bone resorption rate. " 09/01/2008 - "Femur bone density decreased, and urinary excretion of deoxypyridinoline, an index of bone resorption capacity of osteoclasts, increased in ovariectomized animals at the end of the study. " Order ALL the reference details at left...
2.	Prostatic Neoplasms (Prostate Cancer) 08/01/2001 - "Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis." 08/01/1998 - "Also, urinary pyridinoline and deoxypyridinoline were compared in 2 groups of patients with metastatic prostate cancer of the bone who demonstrated progression or positive response to treatment. " 11/01/1996 - "Also, urinary pyridinoline and deoxypyridinoline were compared in 2 groups of patients with metastatic prostate cancer of the bone who demonstrated progression or positive response to treatment. " 08/01/1998 - "Measurement of urinary pyridinoline and deoxypyridinoline may provide a useful marker of prostate cancer metastatic to bone and may be useful in monitoring the response to treatment." 11/01/1996 - "CONCLUSIONS: Measurement of urinary pyridinoline and deoxypyridinoline may provide a useful marker of prostate cancer metastatic to bone and may be useful in monitoring the response to treatment." Order ALL the reference details at left...
3.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 07/01/1997 - "METHODS: Urinary levels (mean +/- SD) of deoxypyridinoline were measured by a competitive immunoassay, and serum levels of P1CP and 1CTP were measured by radioimmunoassay in 30 patients with benign prostatic hyperplasia, 18 patients with prostatic carcinoma without bone metastases, and 27 patients with prostatic carcinoma and bone metastases. " 08/01/1998 - "Levels of urinary pyridinoline and deoxypyridinoline in urine in patients with bony metastatic prostate cancer were significantly greater than levels in patients with benign prostatic hyperplasia or localized prostate cancer. " 04/01/1994 - "Urinary excretion of pyridinoline and deoxypyridinoline was significantly greater in patients with metastatic carcinoma of the prostate compared with patients with either benign prostatic hyperplasia (Mann-Whitney-Wilcoxon rank sum analysis, p < 0.00004 and 0.002, respectively) or localized prostate cancer (Mann-Whitney-Wilcoxon, p < 0.00001 and 0.00005, respectively). " 08/01/1998 - "Urinary pyridinoline and deoxypyridinoline were measured in patients with benign prostatic hyperplasia, clinically localized prostate cancer and prostate cancer with bone metastases. " 07/01/1997 - "RESULTS: Urinary concentrations of deoxypyridinoline (pmol/micromol creatinine) in patients with prostatic carcinoma and bone metastases (10.4 +/- 7.7) were significantly higher than those in similar patients without bone metastases (4.3 +/- 1.3) and those in patients with benign prostatic hyperplasia (3.8 +/- 1.2). " Order ALL the reference details at left...
4.	Osteoporosis 06/01/2007 - "These mice show the clinical signs of osteoporosis, such as elevated levels of urinary deoxypyridinoline (Dpd), decreased bone mineral density (BMD), and a significant loss of trabecular and cortical bone thickness at 12 months of age. " 01/01/2000 - "Synthesis of immunoreagents for development of assays for deoxypyridinoline, a marker for diagnosis of osteoporosis." 01/01/2003 - "Deoxypyridinoline (DPD) in urine, which reflects systemic bone resorption, is considered useful for assessing the effects of osteoporosis treatment. " 06/01/1997 - "Deoxypyridinoline levels were significantly increased in patients with osteoporosis, Paget's disease, and hyperthyroidism. " 05/01/2006 - "[Effect of jiangu granule on levels of urinary deoxypyridinoline and osseous intigrin beta1 mRNA expression in Ovariectomized osteoporosis model rats]" Order ALL the reference details at left...
5.	Neoplasm Metastasis (Metastasis) 10/01/1995 - "Urine deoxypyridinoline was the second most predictive marker of bone metastases. " 01/01/2003 - "Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients." 08/01/2001 - "Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis." 12/01/2000 - "In the symposium, we reported two of our clinical cases, in which urinary deoxypyridinoline, a bone absorption marker, facilitated the discovery of the bone metastasis of lung cancers with negative bone scans. " 07/01/1997 - "CONCLUSION: Urinary deoxypyridinoline, serum P1CP, and serum 1CTP should be useful markers in confirming and monitoring prostatic carcinoma metastases to bone." Order ALL the reference details at left...

Related Drugs and Biologics

1.	pyridinoline
2.	Alkaline Phosphatase
3.	Osteocalcin
4.	Biological Markers (Surrogate Marker)
5.	Collagen Type I (Type I Collagen)
6.	collagen type I trimeric cross-linked peptide
7.	Hydroxyproline (4 Hydroxyproline)
8.	Calcium
9.	risedronic acid (risedronate)
10.	Etidronic Acid (HEDP)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Transplants (Transplant)
3.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
4.	Arthroplasty
5.	Ovariectomy (Oophorectomy)

Best Treatments:
Research Summary Report
on Bone Resorption

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 292 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>